Molecular Diagnostics (MDx) continue to assume a more prominent role in healthcare, and that means new challenges for payers when it comes to reimbursement, coverage decisions, utilization management, and supporting new care models.
Fallon Health is taking these challenges on with an innovative approach to managing a robust MDx program. By focusing on prior authorization, enabling the clinical staff to make informed decisions, and implementing a unique healthcare IT program, Fallon cut review time up to 75%.
It’s possible your organization could do the same. Learn what Fallon Health did to optimize its MDx program in an upcoming AHIP webinar, where Fallon Health executives explain their approach and share how others can apply a similar strategy.
Topics addressed will include:
- The need for unique identification of MDx tests and how to get there
- Strategies to better focus nurses and medical directors on value-added activities
- How to better engage your lab network
Join AHIP and Fallon Health on Tuesday, December 6, at 2:00 p.m. (EST) for this important seminar, where the MDX management problem will be put under the microscope to see some solutions revealed.